Next-Generation Nanobody Therapy Targeting Ent A and Spa for Staphylococcal Infection
VHH-P378 is a humanized single-domain antibody (nanobody) designed to target both Enterotoxin A (Ent A) and Staphylococcal protein A (Spa), two critical virulence factors of Staphylococcus aureus. Currently in the Biological Testing stage, VHH-P378 holds promise as an innovative therapeutic for staphylococcal infection. By specifically binding these bacterial proteins, VHH-P378 aims to disrupt crucial pathways in disease pathogenesis. Its antibody structure and specificity make it a compelling candidate for new anti-infective strategies against complicated or resistant Staphylococcus aureus infections, leveraging emerging nanobody technology for improved clinical outcomes.
| Candidate | VHH-P378 |
| Target | Enterotoxin A (Ent A) Staphylococcal protein A (Spa) |
| Modality | humanized bispecific VHH |
| Indication | Staphylococcal Infection |
Licensing Opportunity
VHH-P378 is currently available for licensing and partnership opportunities. We invite collaborations with biopharmaceutical companies aiming to advance innovative anti-infective therapies addressing significant unmet needs in staphylococcal infection.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P378 |
Modality
VHH-P378 employs a single-domain antibody (nanobody) modality, characterized by its small molecular weight, monomeric structure, and high stability. Expressed efficiently in competent Escherichia coli BL21 cells, this nanobody can be produced at scale with favorable pharmacokinetic properties. The compact structure of VHH-P378 allows for enhanced tissue penetration, including access to challenging sites common in staphylococcal infections, such as biofilms or deep-seated tissues. The inherent stability and specificity of nanobodies like VHH-P378 can improve therapeutic effectiveness while reducing off-target effects, offering significant benefits in treating complex bacterial infections.
Target
Ent A and Spa are pivotal molecular targets in the context of staphylococcal infection. Ent A is a potent exotoxin secreted by Staphylococcus aureus, while Spa is a surface protein involved in immune evasion. Both Ent A and Spa play essential roles in bacterial virulence and pathogenesis, being expressed predominantly in active infection sites and on Staphylococcus aureus cell surfaces. Targeting Ent A and Spa hinders toxin-related damage and interferes with the bacteria's ability to evade host immune responses. VHH-P378’s strategic focus on Ent A and Spa enhances its appeal as a therapeutic asset, potentially addressing resistance and hypervirulent strains of Staphylococcus aureus and supporting its value in anti-infective drug portfolios.
Mechanism of Action
VHH-P378 exerts its therapeutic activity by directly binding to Ent A and Spa on Staphylococcus aureus. Through high-affinity interactions, VHH-P378 can neutralize Ent A, limiting toxin-mediated pathology, and block Spa-mediated immune evasion, thus restoring host immunity. This dual targeting approach interrupts key bacterial survival strategies, supporting bacterial clearance. The nanobody platform of VHH-P378 also enables future adaptation toward multivalent or multispecific molecules, such as antibody-drug conjugates or bispecific formats, broadening its application against evolving bacterial threats and offering attractive development opportunities within the anti-infective and immunotherapy landscapes.
Staphylococcal Infection
Staphylococcal infection comprises a spectrum of diseases ranging from superficial skin lesions to severe invasive conditions such as sepsis, endocarditis, and pneumonia. Globally, Staphylococcus aureus is a leading cause of both community-acquired and healthcare-associated infections, contributing significantly to morbidity and mortality. Current therapies are based on antibiotics, which face increasing limitations due to rising antibiotic resistance and the emergence of multidrug-resistant strains. Alternative strategies such as immunotherapy and targeted biologics are urgently needed to address gaps in efficacy and adverse outcomes associated with conventional treatments. VHH-P378’s mechanism, targeting Ent A and Spa, addresses critical bacterial virulence factors and immune evasion pathways. As a humanized nanobody, VHH-P378 could provide a novel and complementary approach to conventional care, with the potential to overcome resistance and improve patient prognosis in staphylococcal infections.